Visteon Corp SEC Filings

Visteon Corporation filed an amended quarterly report to revise Item 5 and add an omitted disclosure about Rule 10b5-1 trading plans adopted during the quarter ended September 30, 2025. The company also filed new CEO and CFO certifications as exhibits; no financial statements were included and other disclosures were not updated.

Plans disclosed: CEO Sachin S. Lawande’s plan provides for the exercise and sale of up to 99,874 stock options; CFO Jerome Rouquet’s plan provides for the sale of 9,392 shares and the exercise and sale of up to 4,675 shares; SVP Qais Sharif adopted a plan covering 2,200 shares. Shares outstanding were 27,285,922 as of October 16, 2025.

Visteon Corporation reported Q3 2025 results showing lower revenue but stronger profitability. Net sales were $917 million versus $980 million a year ago, while gross margin held at $131 million. Net income attributable to Visteon rose to $57 million from $39 million, and diluted EPS increased to $2.04 from $1.40. The quarter benefited from cost performance and lower restructuring, partly offset by higher net engineering spend and customer pricing pressure.

Year to date, net sales were $2.82 billion versus $2.93 billion in 2024, with net income attributable to Visteon at $187 million (up from $152 million). Operating cash flow reached $292 million for the nine months, lifting cash and equivalents to $762 million at September 30, 2025. The company closed a $55 million UX-focused acquisition (up to $9 million contingent), continued modest buybacks, and paid a $0.275 dividend per share. Term debt stood at $288 million with no revolver borrowings. Subsequent to quarter end, a supplier reported Chinese export controls on certain components; Visteon is pursuing mitigations, with potential impact uncertain.

Visteon Corporation (VC) filed an 8-K announcing it issued a press release with its financial results for the third quarter of 2025. The press release, dated October 23, 2025, is furnished as Exhibit 99.1 under Item 2.02 and incorporated by reference.

The company noted the Exhibit is furnished and not deemed “filed” for liability purposes under the Exchange Act. Item 7.01 (Regulation FD) cross-references the same disclosure. Visteon’s common stock trades on The NASDAQ Stock Market under the symbol VC.

Insider sale by Visteon director. Director Francis M. Scricco reported two open-market sales of VISTEON CORP (VC) common stock on 08/22/2025, disposing of 4,338 shares at $120.53 and 12 shares at $121.37. After the transactions he beneficially owned 2,792 shares. The Form 4 was signed on behalf of Mr. Scricco by the company secretary on 08/25/2025.

Visteon Corporation (VC) filed a Form 144 reporting a proposed sale of 4,350 shares of common stock through Merrill Lynch (100 Campus Drive, Florham Park, NJ) with an approximate aggregate market value of $522,482.00. The filing lists 27,276,339 shares outstanding and an approximate sale date of 08/22/2025 on the NYSE. The securities were acquired in open-market purchases: 1,150 shares on 12/04/2012 and 3,200 shares on 06/13/2014, with full payment made at acquisition. The filer reports no securities sold in the past three months and includes the standard representation that the signer is not aware of undisclosed material adverse information.

Francis M. Scricco, a director of Visteon Corporation (VC), reported two open-market stock sales on 08/19/2025. He sold 3,842 shares at $121.78 and 200 shares at $122.025. After the first sale he beneficially owned 7,342 shares and after the second sale he beneficially owned 7,142. The Form 4 was signed on behalf of Mr. Scricco by Visteon's secretary on 08/21/2025.

Visteon Corporation (VC) filed a Form 144 notifying a proposed sale of 4,042 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $492,284.14, scheduled approximately for 08/19/2025 on NASDAQ. The notice reports total shares outstanding of 27,276,339. The shares originated from restricted stock vesting: 1,850 shares vested 06/08/2024, 1,189 vested 06/23/2023, and 1,003 vested 06/10/2022, each received as compensation. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.

Robert R. Vallance, Senior Vice President of Visteon Corporation (VC), reported a sale of 2,000 shares of the company's common stock on 08/13/2025 at a price of $120 per share. After the transaction, he beneficially owned 18,838 shares directly. The filing states the trades were executed under a Rule 10b5-1 trading plan that Vallance adopted on March 5, 2025. The Form 4 was signed on behalf of the reporting person on 08/14/2025. The report identifies Vallance as an officer (Senior Vice President) and was filed as an individual Form 4.

Visteon Corporation received a Schedule 13G/A (Amendment No. 2) disclosing that American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research beneficially own 2,222,551 shares of common stock, representing 8.2% of the class. The cover pages report sole voting power of 2,173,962 shares and sole dispositive power of 2,222,551 shares. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The position is reported as of 06/30/2025, the filing is signed 08/14/2025, and an exhibit records consent to the joint filing.